UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 144 Filer Information

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

### 144: Filer Information

Filer CIK 0001687968
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

**Submission Contact Information** 

Name

Phone

E-Mail Address

### 144: Issuer Information

Name of Issuer Dynavax Technologies Corporation

SEC File Number 001-34207

2100 Powell Street

Suite 720 Emeryville

Address of Issuer Emeryville CALIFORNIA

94608

Phone 510-848-5100

Name of Person for Whose Account the Securities are To Be Sold BAIN CAPITAL LIFE SCIENCES FUND, LP

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Affiliate

## **144: Securities Information**

| Title of the Class of<br>Securities To Be Sold | Name and Address of<br>the Broker                                  | Number of<br>Shares or<br>Other Units<br>To Be Sold | Aggregate<br>Market Value |           |            | Name the<br>Securities<br>Exchange |
|------------------------------------------------|--------------------------------------------------------------------|-----------------------------------------------------|---------------------------|-----------|------------|------------------------------------|
| Common Stock                                   | Goldman Sachs & Co.<br>LLC<br>200 West Street<br>New York NY 10282 | 1360717                                             | 20070575                  | 128797357 | 08/08/2023 | NASDAQ                             |

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

### 144: Securities To Be Sold

| Title of the | Date you | Nature of   | Name of     | Is   | Date  | Amount of  | Date of | Nature of |
|--------------|----------|-------------|-------------|------|-------|------------|---------|-----------|
| Class        | Acquired | Acquisition | Person from | this | Donor | Securities | Payment | Payment * |

|              |            | Transaction                                                          | Whom<br>Acquired | a Acquired Gift? | Acquired |                 |
|--------------|------------|----------------------------------------------------------------------|------------------|------------------|----------|-----------------|
| Common Stock | 08/12/2019 | Purchase of<br>Common Stock in<br>an underwritten<br>public offering | Underwriter      |                  | 6826266  | 08/12/2019 Cash |
| Common Stock | 05/27/2020 | Purchase of<br>Common Stock in<br>an underwritten<br>public offering | Underwriter      |                  | 907145   | 05/27/2020 Cash |

<sup>\*</sup> If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

# 144: Securities Sold During The Past 3 Months

| Name and Address of Seller                                                       | Title of Securities Sold | Date of<br>Sale | Amount of<br>Securities<br>Sold | <b>Gross Proceeds</b> |
|----------------------------------------------------------------------------------|--------------------------|-----------------|---------------------------------|-----------------------|
| Bain Capital Life Sciences Fund, L.P.<br>200 Clarendon Street<br>Boston MA 02116 | Common Stock             | 05/18/2023      | 907145                          | 9570380               |
| BCIP Life Sciences Associates, LP<br>200 Clarendon Street<br>Boston MA 02116     | Common Stock             | 05/18/2023      | 92855                           | 979620                |
| Bain Capital Life Sciences Fund, L.P.<br>200 Clarendon Street<br>Boston MA 02116 | Common Stock             | 06/14/2023      | 453572                          | 5751293               |
| BCIP Life Sciences Associates, LP<br>200 Clarendon Street<br>Boston MA 02116     | Common Stock             | 06/14/2023      | 46428                           | 588707                |

## 144: Remarks and Signature

Remarks

Date of Notice 08/08/2023

**ATTENTION:** 

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Andrew Hack, as Partner of Bain Capital Life Sciences Investors, LLC

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)